SNSW(SH:688117) Shang Hai Zheng Quan Bao·2025-08-14 18:34Group 1 - The core viewpoint of the report is to provide a detailed account of the fundraising activities and the management of raised funds by Chengdu Saintno Biological Technology Co., Ltd. for the first half of 2025 [4][6][26] - The company successfully raised a total of RMB 358 million through the issuance of 20 million shares at a price of RMB 17.90 per share, with a net amount of RMB 285.2 million after deducting issuance costs [4][6] - As of June 30, 2025, the company has utilized RMB 12.57 million of the raised funds for investment projects, with a cumulative usage of RMB 295.9 million [6][8] Group 2 - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used according to regulatory requirements [7][25] - There were no instances of changing the use of raised funds or using idle funds for temporary liquidity needs during the reporting period [10][13] - The company has a plan to use up to RMB 70 million of temporarily idle self-owned funds for entrusted financial management, aiming to enhance the efficiency of fund usage without affecting daily operations [20][26]